Serena Di Cosimo
The Breast Cancer Research Foundation
CancerSurgeryOncologyMetastatic breast cancerChemotherapyAnthracyclineLapatinibNeoadjuvant therapyDiseaseTrastuzumabTriple-negative breast cancerEpirubicinTargeted therapyGynecologyCancer researchRadiation therapyBreast cancerMedicinePI3K/AKT/mTOR pathwayGastroenterology
140Publications
28H-index
5,021Citations
Publications 135
Newest
#1Maria Alice Franzoi (ULB: Université libre de Bruxelles)H-Index: 3
#2Daniel Eiger (ULB: Université libre de Bruxelles)H-Index: 4
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 14 authors...
BACKGROUND There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors. METHODS Pooled analysis of individual patient-level data from MONARCH 2 and 3 trials. Patients were classified according to baseline BMI into underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2) and divided into two treatment groups: abemaciclib +...
4 CitationsSource
#1Catherine DeprettoH-Index: 2
#2Alessandro Liguori (University of Milan)H-Index: 2
Last. Gianfranco ScaperrottaH-Index: 7
view all 7 authors...
PURPOSE To investigate the agreement between automated breast ultrasound (ABUS) and hand-held ultrasound (HHUS) in surveillance of women with a history of breast cancer in terms of recurrences or new ipsilateral or contralateral breast cancer. METHODS The institutional review board approved this retrospective study and informed consent was waived. From April to June 2016, women with dense breasts undergoing annual surveillance with mammography and HHUS after breast-conserving surgery were offere...
Source
#1Serena Di CosimoH-Index: 28
Last. Marco DanovaH-Index: 28
view all 33 authors...
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT) are critical to their management through the evolving COVID-19 pandemic. The AIOM-L CORONA was a multicenter, observational, ambispective, cohort study, with the intended participation of 26 centers in the Lombardy region (Italy). A total of 231 cases were included between March and Se...
Source
#1N. ChicH-Index: 4
#2Stephen J LuenH-Index: 12
Last. Sherene LoiH-Index: 73
view all 14 authors...
Source
#1Jose Perez-GarciaH-Index: 20
Last. Javier CortesH-Index: 60
view all 22 authors...
Background: P led to a meaningful improvement in clinical outcomes when used in combination with endocrine therapy for first- or later-line regimen in HR[+]/HER2[-] MBC. Grade 3-4 neutropenia was the most common adverse event (AE) in the P-containing regimens. Although venous thromboembolic events (VTE) have been rarely reported in registrational trials, a systematic review and meta-analysis of randomized controlled trials demonstrated a higher rate of these AEs. Moreover, rare but severe cases ...
Source
#1Serena Di CosimoH-Index: 28
#2Luca PorcuH-Index: 16
Last. Fatima Cardoso (Champalimaud Foundation)H-Index: 60
view all 3 authors...
Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic management of HR+/HER2-advanced breast cancer by prolonging progression-free and overall survival when given in combination with endocrine therapy. In this article, available data from PALLAS and mona...
Source
#1Samuel Martel (Université de Sherbrooke)H-Index: 7
#2Matteo LambertiniH-Index: 28
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 16 authors...
BACKGROUND The association between obesity and prognosis in HER2-positive early breast cancer remains unclear, with limited data available. This study aimed to determine the impact of body mass index (BMI) at baseline and weight change after 2 years on outcomes of patients with HER2-positive early breast cancer. METHODS ALTTO was a randomized phase III trial in patients with HER2-positive early breast cancer. BMI was collected at randomization and 2 years after. WHO BMI categories were used: und...
Source
#2Jose Perez-GarciaH-Index: 20
Last. Javier CortesH-Index: 60
view all 15 authors...
Source
#1Serena Di CosimoH-Index: 28
#2Luca PorcuH-Index: 16
Last. Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 48
view all 13 authors...
Source
1 CitationsSource
12345678910
Close Researchers